search
Back to results

Wound Infections Following Implant Removal (WIFI)

Primary Purpose

Surgical Wound Infection

Status
Completed
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
Cephalozin
Sodium chloride
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Surgical Wound Infection focused on measuring Implant Removal, Antibiotic Prophylaxis, Postoperative wound infection, Orthopedics

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients ≥18 years and ≤75 years of all ethnic backgrounds
  • Implant removal following foot, ankle and/or lower leg surgery

Exclusion Criteria:

  • Removing and re-implanting osteosynthesis material in the same session
  • Active wound infection or (plate) fistula
  • Antibiotic treatment at time of elective implant removal for a concomitant disease or infection
  • A medical history of an allergic reaction to a cephalosporin, penicillin, or any other β-lactam antibiotic.
  • Insufficient comprehension of the Dutch language to understand the patient information to make an informed decision to participate.
  • Kidney disease (eGFR <60 ml/min/1.73m^2).
  • Treatment with probenecide, anticoagulants (see SPC)
  • Pregnancy and lactation

Sites / Locations

  • Medisch Centrum Alkmaar
  • Flevoziekenhuis
  • Amstelland Ziekenhuis
  • Academic Medical Center
  • BovenIJ Ziekenhuis
  • Onze Lieve Vrouwe Gasthuis
  • Sint Lucas Andreas Ziekenhuis
  • VU Medisch Centrum
  • Gelre Ziekenhuizen
  • Rode Kruis Ziekenhuis
  • Amphia Ziekenhuis
  • Reinier de Graaf
  • MC Haaglanden
  • Deventer Ziekenhuis
  • Catharina Ziekenhuis
  • Elkerliek Ziekenhuis
  • Tergooiziekenhuizen
  • Spaarne Ziekenhuis
  • Westfries Gasthuis
  • Rijnland Ziekenhuis
  • Vlietland Ziekenhuis

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

antibiotic prophylaxis

No antibiotic prophylaxis

Arm Description

a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)

a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).

Outcomes

Primary Outcome Measures

Postoperative wound infection (POWI)
The primary outcome variable is a POWI within 30 days after implant removal as defined by the criteria applied by the Centers for Disease and Control.

Secondary Outcome Measures

Health-related quality of life
Health-related quality of life (as measured by the EQ-5D questionnaire)
Functional outcome
Functional outcome following implant removal as assessed with the Lower Extremity Functional Scale (LEFS). The LEFS can be used by clinicians as a measure of patients' initial function, ongoing progress and outcome, as well as to set functional goals. The LEFS can be used to evaluate the functional impairment of a patient with a disorder of one or both lower extremities. It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention
Patient satisfaction
Patient satisfaction following implant removal as measured by a ten-point Visual Analog Scale
Health care resources utilization
Health care resources utilization at baseline, 1 month and 6 months after implant removal (including amongst others, number of visits to the general practitioner and use of home care organizations) as measured by way of a combination of the Dutch iMTA Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) (adapted to the study setting).

Full Information

First Posted
August 25, 2014
Last Updated
December 21, 2016
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, AO Research Fund
search

1. Study Identification

Unique Protocol Identification Number
NCT02225821
Brief Title
Wound Infections Following Implant Removal
Acronym
WIFI
Official Title
Antibiotic Prophylaxis to Prevent Wound Infections Following Implant Removal
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
November 2014 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, AO Research Fund

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In the Netherlands about 18,000 surgical procedures with implant removal are annually performed after fracture healing, of which 30-80% concern the foot, ankle and lower leg region. For clean surgical procedures, the rate of postoperative wound infections (POWIs) should be less than 5%. However, rates of 10-12% following implant removal, specifically after foot, ankle and lower leg fractures are reported. Currently, surgeons decide individually if antibiotics prophylaxis is given, since no guideline exists. This leads to undesirable practice variation. Therefore, the investigators propose a double-blind randomized controlled trial (RCT) in patients scheduled for implant removal following a foot, ankle or lower leg fracture, to assess the (cost-)effectiveness of a single gift of antibiotic prophylaxis. Primary outcome is a POWI within 30 days after implant removal. Secondary outcomes are quality of life, functional outcome at 30 days and 6 months after implant removal and costs. With 2 x 250 patients a decrease in POWI from 10% to 3.3% (expected rate in clean-contaminated elective orthopedic trauma procedures) can be detected (Power=80%, 2-sided alpha=5%, including 15% lost to follow up). If the assumption of the investigators, that prophylactic antibiotics prior to implant removal reduces the infectious complication rate, is confirmed by this RCT, this will offer a strong argument to adopt a single gift of antibiotic prophylaxis as standard practice of care. This will reduce the incidence of POWIs and consequently will lead to less physical and social disabilities and health care use. In addition, it will decrease the rate of use of empiric broad-spectrum antibiotics (and antibiotic resistance) prescribed upon suspicion or diagnosis of a POWI. A preliminary, conservative estimation suggests yearly cost savings in the Netherlands of €3.5 million per year.
Detailed Description
See study protocol

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Wound Infection
Keywords
Implant Removal, Antibiotic Prophylaxis, Postoperative wound infection, Orthopedics

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
500 (Actual)

8. Arms, Groups, and Interventions

Arm Title
antibiotic prophylaxis
Arm Type
Active Comparator
Arm Description
a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
Arm Title
No antibiotic prophylaxis
Arm Type
Placebo Comparator
Arm Description
a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
Intervention Type
Drug
Intervention Name(s)
Cephalozin
Other Intervention Name(s)
Kefzol
Intervention Description
1000 mg Cephalozin
Intervention Type
Other
Intervention Name(s)
Sodium chloride
Other Intervention Name(s)
NaCl 0.9%
Intervention Description
10 cc of NaCl 0.9%
Primary Outcome Measure Information:
Title
Postoperative wound infection (POWI)
Description
The primary outcome variable is a POWI within 30 days after implant removal as defined by the criteria applied by the Centers for Disease and Control.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Health-related quality of life
Description
Health-related quality of life (as measured by the EQ-5D questionnaire)
Time Frame
baseline, one month, 6 months
Title
Functional outcome
Description
Functional outcome following implant removal as assessed with the Lower Extremity Functional Scale (LEFS). The LEFS can be used by clinicians as a measure of patients' initial function, ongoing progress and outcome, as well as to set functional goals. The LEFS can be used to evaluate the functional impairment of a patient with a disorder of one or both lower extremities. It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention
Time Frame
baseline, 1 month, 6 months
Title
Patient satisfaction
Description
Patient satisfaction following implant removal as measured by a ten-point Visual Analog Scale
Time Frame
1 month, 6 months
Title
Health care resources utilization
Description
Health care resources utilization at baseline, 1 month and 6 months after implant removal (including amongst others, number of visits to the general practitioner and use of home care organizations) as measured by way of a combination of the Dutch iMTA Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) (adapted to the study setting).
Time Frame
baseline, 1 month, 6 months
Other Pre-specified Outcome Measures:
Title
Costs
Description
Costs (economic evaluation including budget impact analysis): the economic evaluation of antibiotic prophylaxis in patients scheduled for implant removal (following a foot, ankle or lower leg fracture) against no prophylaxis as its best alternative will be performed as a cost-effectiveness (CEA) as well as a cost-utility (CUA) analysis.
Time Frame
Costs per quality adjusted life year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients ≥18 years and ≤75 years of all ethnic backgrounds Implant removal following foot, ankle and/or lower leg surgery Exclusion Criteria: Removing and re-implanting osteosynthesis material in the same session Active wound infection or (plate) fistula Antibiotic treatment at time of elective implant removal for a concomitant disease or infection A medical history of an allergic reaction to a cephalosporin, penicillin, or any other β-lactam antibiotic. Insufficient comprehension of the Dutch language to understand the patient information to make an informed decision to participate. Kidney disease (eGFR <60 ml/min/1.73m^2). Treatment with probenecide, anticoagulants (see SPC) Pregnancy and lactation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manouk Backes, MD, MSc
Organizational Affiliation
Academic Medical Center/Sint Lucas Andreas Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tim Schepers, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Study Director
Facility Information:
Facility Name
Medisch Centrum Alkmaar
City
Alkmaar
Country
Netherlands
Facility Name
Flevoziekenhuis
City
Almere
Country
Netherlands
Facility Name
Amstelland Ziekenhuis
City
Amstelveen
Country
Netherlands
Facility Name
Academic Medical Center
City
Amsterdam
Country
Netherlands
Facility Name
BovenIJ Ziekenhuis
City
Amsterdam
Country
Netherlands
Facility Name
Onze Lieve Vrouwe Gasthuis
City
Amsterdam
Country
Netherlands
Facility Name
Sint Lucas Andreas Ziekenhuis
City
Amsterdam
Country
Netherlands
Facility Name
VU Medisch Centrum
City
Amsterdam
Country
Netherlands
Facility Name
Gelre Ziekenhuizen
City
Apeldoorn
Country
Netherlands
Facility Name
Rode Kruis Ziekenhuis
City
Beverwijk
Country
Netherlands
Facility Name
Amphia Ziekenhuis
City
Breda
Country
Netherlands
Facility Name
Reinier de Graaf
City
Delft
Country
Netherlands
Facility Name
MC Haaglanden
City
Den Haag
Country
Netherlands
Facility Name
Deventer Ziekenhuis
City
Deventer
Country
Netherlands
Facility Name
Catharina Ziekenhuis
City
Eindhoven
Country
Netherlands
Facility Name
Elkerliek Ziekenhuis
City
Helmond
Country
Netherlands
Facility Name
Tergooiziekenhuizen
City
Hilversum
Country
Netherlands
Facility Name
Spaarne Ziekenhuis
City
Hoofddorp
Country
Netherlands
Facility Name
Westfries Gasthuis
City
Hoorn
Country
Netherlands
Facility Name
Rijnland Ziekenhuis
City
Leiderdorp
Country
Netherlands
Facility Name
Vlietland Ziekenhuis
City
Schiedam
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
24038057
Citation
Backes M, Schep NW, Luitse JS, Goslings JC, Schepers T. Indications for implant removal following intra-articular calcaneal fractures and subsequent complications. Foot Ankle Int. 2013 Nov;34(11):1521-5. doi: 10.1177/1071100713502466. Epub 2013 Sep 13.
Results Reference
background
PubMed Identifier
25972101
Citation
Backes M, Dingemans SA, Schep NW, Bloemers FW, Van Dijkman B, Garssen FP, Haverlag R, Hoogendoorn JM, Joosse P, Mirck B, Postma V, Ritchie E, Roerdink WH, Sintenie JB, Soesman NM, Sosef NL, Twigt BA, Van Veen RN, Van der Veen AH, Van Velde R, Vos DI, De Vries MR, Winkelhagen J, Goslings JC, Schepers T. Wound Infections Following Implant removal below the knee: the effect of antibiotic prophylaxis; the WIFI-trial, a multi-centre randomized controlled trial. BMC Surg. 2015 Feb 6;15:12. doi: 10.1186/1471-2482-15-12.
Results Reference
background
PubMed Identifier
29279933
Citation
Backes M, Dingemans SA, Dijkgraaf MGW, van den Berg HR, van Dijkman B, Hoogendoorn JM, Joosse P, Ritchie ED, Roerdink WH, Schots JPM, Sosef NL, Spijkerman IJB, Twigt BA, van der Veen AH, van Veen RN, Vermeulen J, Vos DI, Winkelhagen J, Goslings JC, Schepers T; WIFI Collaboration Group. Effect of Antibiotic Prophylaxis on Surgical Site Infections Following Removal of Orthopedic Implants Used for Treatment of Foot, Ankle, and Lower Leg Fractures: A Randomized Clinical Trial. JAMA. 2017 Dec 26;318(24):2438-2445. doi: 10.1001/jama.2017.19343. Erratum In: JAMA. 2018 Mar 13;319(10 ):1051.
Results Reference
derived

Learn more about this trial

Wound Infections Following Implant Removal

We'll reach out to this number within 24 hrs